Mini-Focus: Heart Failure Outcomes and EndpointsClinical ResearchUse of the Win Ratio in Cardiovascular Trials
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Jhund's employer, the University of Glasgow, has been remunerated by Novartis for work on the PARADIGM-HF and PARAGON trials and by AstraZeneca for his time working on the DAPA-HF and DELIVER trials; and has received consulting fees from Novartis and Cytokinetics and research support from Boehringer Ingelheim. Dr. Claggett is a consultant for Amgen, Novartis, Myokardia, and AO Biome. Dr. Solomon has received research support from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol-Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, U.S. National Institutes of Health/National Heart Lung Blood Institute, Novartis, Sanofi, Pasteur, and Theracos; and is a consultant for Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Bristol-Myers Squib, Cardior, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GlaxoSmithKline, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, and Tenaya. Dr. Pocock has received honoraria for Data Safety and Monitoring Boards for trials sponsored by Pfizer, Novartis, and AstraZeneca. Dr. Petrie has received research support from Novartis and Boehringer Ingelheim; and is a consultant for NovoNordisk, Boehringer Ingelheim, Novartis, Takeda, Napp, and Corvia. Dr. McMurray is a consultant for and/or has received compensation from Abbott, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardurion, Cyclerion Therapeutics, DalCor, GlaxoSmithKline, Merck, Novartis, Theracos, and Vifor-Fresenius with all fees paid to his employer, Glasgow University. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Heart Failure author instructions page.